Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2013 April ; 22(4): 540–552. doi:10.1158/1055-9965.EPI-12-1347.

Squamous dysplasia – the precursor lesion for esophageal squamous cell carcinoma

Philip R Taylor¹, Christian C Abnet², and Sanford M Dawsey²

¹Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH

²Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, NCI, NIH

Abstract

Esophageal squamous cell carcinoma (ESCC) accounts for 80% of all esophageal cancers worldwide, and esophageal squamous dysplasia (ESD) is the only histopathology that predicts the development of ESCC. The prevalence of ESD parallels rates of invasive ESCC, and is typically found in 25% or more of adults above the age of 35 years in populations in north central China, where risk for ESCC is among the highest in the world. Results of chemoprevention and early detection studies to prevent progression of ESD suggest that these approaches, coupled with emerging endoscopic therapies, offer promise for the prevention of esophageal cancer mortality in high-risk populations. Future research on ESD and ESCC should focus on finding additional modifiable risk factors and on identifying biomarkers to incorporate into early detection strategies.

1. Introduction and Historical Context

Rates

Esophageal cancer (EC) is the 8th most common cancer and the 6th most common cause of cancer death in the world, with an estimated 482,000 new cases and 407,000 deaths in 2008 (1). There are two main histopathologic types of EC, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). EAC, due largely to gastroesophageal reflux disease and obesity, has increased dramatically in the past 30+ years and is now the predominant type in the U.S. and most other Western countries. Worldwide, however, ESCC dominates, with 80% of all cases, due largely to high rates in many developing countries. China, with its high rates and large population, accounts for over half of all EC deaths in the world, and nearly all are ESCC. High rates of EC are found along geographic belts, one following the ancient Silk Road from north central China through the central Asian republics to northern Iran, and one from eastern to southern Africa (Fig 1). This mini-review will focus only on precursors of ESCC.

Precursors

Although early studies conducted in high-risk areas suggested that esophagitis was a precursor for ESCC (2), subsequent studies have shown that dysplasia is the only histopathology that predicts the development of ESCC. Qiu and Yang (3) were the first to provide evidence that esophagitis alone was nonspecific and dysplasia was a precancerous state, but the most definitive assessment of risk from squamous esophageal histology has come from follow-up of 682 participants in the Linxian Dysplasia Nutrition Intervention Trial (NIT) who participated in an endoscopy survey in 1987 (4). A comparison of initial biopsy diagnoses with the occurrence of ESCC over the subsequent 3.5 years showed that only dysplasia predicted development of ESCC, and that increasing grades of dysplasia predicted increased risk: compared to normal, relative risks (95% confidence intervals) were 2.2 (0.7–7.5) for mild dysplasia, 15.8 (5.9–42.2) for moderate dysplasia, 72.6 (29.8–176.9)

for severe dysplasia, 22.9 (6.7–78.0) for dysplasia not otherwise specified, and 62.5 (24.1–161.9) for carcinoma-in-situ. Of note, dysplasia not otherwise specified (NOS) and moderate dysplasia risks were similar, as were risks for carcinoma-in-situ and severe dysplasia. Further follow-up of this same endoscopic cohort for a total of 13.5 years corroborated the previous risk estimates and provided more precise quantification. Over the full follow-up period ESCC developed in 8% of participants with normal histology, but 24% with mild dysplasia, 50% with moderate dysplasia, 74% with severe dysplasia, 58% with dysplasia NOS, and 75% with carcinoma-in-situ (Fig 2) (5).

2. Histologic and Molecular Characterization

Histologic Characterization

Histologic criteria for the ESCC precursor lesion, esophageal squamous dysplasia (ESD), were initially described in the 1970s (6–9) and modified in the 1980s based on experience in China (10). Squamous dysplasia requires the presence of nuclear atypia (enlargement, pleomorphism, and hyperchromasia), loss of normal cell polarity, and abnormal tissue maturation, without invasion of epithelial cells through the basement membrane. Compared to normal (Fig 3a), in mild dysplasia these abnormalities are confined to the lower third of the epithelium (Fig 3b), while in moderate dysplasia they are present in the lower two-thirds of the epithelium (Fig 3c), and in severe dysplasia they also involve the upper third of the epithelium (Fig 3d). Full thickness involvement of the epithelium, called carcinoma in situ by some, is considered synonymous with severe dysplasia based on their similar histologic appearance and risk of progression to invasive ESCC. A final category, dysplasia NOS, indicates that dysplasia is present but cannot be graded accurately because of poor tissue orientation or artifact, and has progression risk approximating that of moderate dysplasia; re-biopsy to accurately stage to dysplasia would be necessary to define cancer risk.

Molecular Characterization

Numerous molecular alterations in ESCC tumors have been identified. Among them, *TP53* alterations are the most common. One study of 56 ESCC cases from north central China found at least one genetic alteration in *TP53* in 96% of the tumors studied, including mutations (77%), allelic loss within the gene (73%), and/or loss of heterozygosity (LOH) at the *TP53* microsatellite marker (80%); and three-quarters of the cases had two or more such alterations (11). In a study conducted in northeastern Iran, 90% of the 119 ESCC cases evaluated had a *TP53* mutation, including 11 with two or three mutations (12). The *TP53* mutation pattern observed in this study was heterogeneous, in a manner suggestive of environmental exposures. Typical hotspots were only infrequently mutated, while 40% of altered bases were at mutagenesis sites known to be associated with polycyclic aromatic hydrocarbon exposure, and the mutation patterns differed by the reported temperature of the tea consumed. Another study of 60 ESCCs from north central China observed at least one alteration in *p16INK4a* in 68% of cases (50% aberrant methylation, 17% microsatellite LOH) and at least one alteration in *p15INK4b* in 50% (35% homozygous deletion, 47% microsatellite LOH, 18% aberrant methylation) (13). In addition, RNA array expression studies have found numerous other dysregulated genes as gain- and loss-of-function candidates in ESCC (14). Recently whole exome sequencing found that ESCCs had an average of 83 mutations per tumor, and that the most frequent mutations in ESCC occurred in *TP53* (92% of the 12 cases sequenced), *NOTCH1* (33%), *NOTCH3* (25%), and *FBXW7* (17%) (15).

Premalignant lesions of the squamous esophagus have been studied much less than ESCC tumors. The most common molecular-oriented approach applied to premalignant lesions thus far has been immunohistochemical (IHC) studies of the expression of one or more

candidate proteins. Numerous studies have shown overexpression of p53 protein in squamous dysplasia compared to normal tissue. In one study, for example, 92% of 12 dysplasia samples and 0% of 14 normal tissue samples obtained from the resection specimens of 44 ESCC cases were p53 positive, as were all five dysplasia biopsies and 50% of six normal biopsies taken from 51 cancer-free patients (16). Other proteins shown to have increased expression in dysplasia include CD44 (17); TGF beta I (positive in 81% of dysplasia vs 37% of normal samples) (18); PCNA (positive in 75% of dysplasia vs 55% of normal) (19, 20); FADD, CDC25B, fascin, CK14, LAMC2, and SPARC (21); p16 (positive in 88% of dysplasia vs 10% of normal), p15 (positive in 73% of dysplasia vs 0% in normal), p14 (positive in 100% of dysplasia vs 15% of normal) (22); and PTCH1 (positive in 21% of dysplasia vs 0% of normal) (23). Decreased expression in dysplasia compared to normal has been observed for TGF beta receptor II (81% positive in dysplasia vs 98% positive in normal) (18); esophagin (positive in 9% of dysplasia vs 53% normal) (20); and Fas, caspase 8, CK4, annexin 1 (21).

Nucleic acid-based studies of precursors have shown increased allelic loss (pointing to potential tumor suppressor gene inactivation sites) with increasing grade of dysplasia at a wide variety of microsatellite loci (i.e., 3p, 4p, 5q, 8p, 9p, 9q, 10p, 11p, 13q, and 17p) (24–27). Mutation studies in esophageal squamous precursors have been limited to *TP53*, where missense mutations were evident early in esophageal carcinogenesis (four of 11 samples with dysplasia vs one of three normal epithelia) (28). Several studies have evaluated promoter hypermethylation in candidate genes in esophageal precursors (29–32). Most of these studies showed little or no hypermethylation in normal tissue, with progressively more hypermethylation as morphology advanced toward ESCC. Of the 30+ different genes evaluated, only *p16INK4a* was examined in all four studies, and it showed hypermethylation in from 4% to 38% of lesions with dysplasia.

While a reasonable number of studies have reported molecular characteristics in esophageal squamous premalignancy, these studies often used different designs and analytic approaches, few studies examined the same targets, objective and quantitative assessments were not typical, and sample sizes were generally small. Taken together, these differences limit the comparability and overall conclusions that can be drawn from the studies.

More recently, high throughput genome-wide methods in the analysis of patterns of RNA expression (33–35), differential methylation, and gene copy number have shown promise in distinguishing patients with and without high-grade squamous dysplasia (36). Real progress in identifying the changes driving esophageal squamous carcinogenesis will require the comprehensive application of new high throughput technologies, including whole genome sequencing, RNA sequencing, and global epigenomics, in addition to objective, quantified characterization of protein expression, all analyzed in a fully integrated manner.

Genetic susceptibility to ESCC is evidenced by the identification of tylosis, a rare autosomal dominant skin disorder characterized by hyperkeratosis of the palms and soles reported in the literature in three families (37), and recent findings from genome-wide association studies (GWAS), where up to 17 loci have been associated with ESCC risk in Chinese populations (38–41). While cumulative risk of ESCC to age 70 in family members with tylosis is estimated at over 90%, risk associated with alleles identified in GWAS to date is modest (e.g., the per allele odds ratio for *PLCE1* is 1.34). Experience with breast cancer suggests that even the combination of all GWAS hits together is unlikely to demonstrably improve clinical risk prediction (42). There are, as yet, no published studies on the genetics or genomics of susceptibility to ESD.

3. Descriptive Epidemiology and Etiology

Etiology of ESCC

While all ESCCs share a common histology, etiologically there are two distinctly different ESCC diseases. ESCC occurs in developed countries at rates that are low to moderate, and etiology there can be attributed almost entirely to exposure to alcohol and tobacco (43). In contrast, in the economically less developed countries in eastern and central Asia and eastern and southern Africa, where rates of ESCC are the highest in the world, alcohol and tobacco exposure have little or no role. The Taihang Mountain region of north central China has the highest ESCC incidence in China, with rates in women that are nearly as high as in men despite the fact that very few women use tobacco or drink alcohol (44, 45). Similarly, northern Iran has high rates, yet alcohol is consumed by less than 2% of the population due to religious proscription (46). Studies in high-risk regions suggest that exposure to carcinogens such as polycyclic aromatic hydrocarbons (47), opium (46), poor nutrition (48–52), and thermal damage (45, 53) are major risks, while tobacco exposure plays only a minor role (44–46). Despite these differences in etiology, both high- and low-rate ESCC share dysplasia as their precursor lesion, and thus approaches to screening and treatment are common to both.

Prevalence of Precursor Lesions

The prevalence of esophageal squamous dysplasia has been documented best in the areas of the world where ESCC rates are highest, specifically in Iran and China, where reports from 11 surveys have been published (Table 1). Dysplasia prevalence has varied from 3% to 38% in these surveys, due in part to differences in the populations (i.e., risk level, age and gender differences, whether or not persons had a prior diagnosis of dysplasia, and the presence of symptoms), endoscopy methods (i.e., use of Lugol's iodine on the mucosa, number of biopsies taken), and the pathology criteria used (2, 3, 10, 54–59). The earliest surveys found lower rates, most likely due to different pathology criteria and lack of mucosal iodine staining. The two surveys from Iran both found 4% prevalence (54, 59) while, with rare exception, the Taihang Mountain region in China has shown dysplasia prevalences that were much higher, exceeding 20%.

The five most recent surveys in north central China reported grades of dysplasia in addition to total dysplasia prevalence (10, 55–58). In these surveys, the most common grade of dysplasia was mild (median 10.6%, range 2.6% to 14.0%), followed by moderate (7.8%, 0.2% to 12.0%), and severe (including CIS) (5.3%, 0.4% to 7.4%).

Risk Factors for Dysplasia

The few studies conducted to evaluate risk factors for esophageal squamous dysplasia have all been conducted in the high-risk Taihang Mountain region in China. These studies have focused on known or suspected risk factors for cancer and have not included wide-ranging assessments of risk for esophageal squamous dysplasia associated with other exposures.

A screening study of 724 healthy adults aged 40 to 65 years from Linxian conducted in 2002 (57) served as the basis for four evaluations of risk factors for dysplasia. Among the 720 subjects who underwent endoscopy during this study, the prevalence of risk factors among the 230 subjects with dysplasia was compared to the prevalence among 490 subjects without dysplasia. Questionnaire-based analyses found significantly increased risk for dysplasia among persons who had a positive family history of cancer (OR=1.57, 95% CI=1.13–2.18), had higher systolic blood pressure (1.11/10 mm Hg, 1.03–1.19), used a heating stove without a chimney (2.22, 1.27–3.86), and had lost more but not all of their teeth (1.91 for 12–31 vs <4 teeth lost, 1.17–3.15). Although not quite statistically significant, risk of

dysplasia was lower in households with smaller size and higher income (60). Higher serum 25-hydroxyvitamin D concentrations were also associated with increased risk for dysplasia in this endoscopy cohort (OR=1.86, 95% CI=1.35–2.62 for high vs low quartile) (61). Serum pepsinogens (PG) I and II were evaluated in 125 dysplasia cases and 250 sex-matched controls from this same cohort. In this study PG I levels did not differ between dysplasia cases and noncases, however, the PG I/II ratio showed a strong dose-response relation, with lower PG I/II levels associated with increased risk of dysplasia (OR=2.12, 95% CI=1.08–4.18 for low vs high quartile), consistent with a role for gastric atrophy in the etiology of esophageal dysplasia (62). Finally, the association between HPV and ESCC has been inconsistent (63–68). In precursors, one study of HPV DNA in esophageal cells from balloon cytology found no association with dysplasia (69), while two other studies did observe HPV DNA in dysplasia (70, 71).

An endoscopic survey from Anyang among 7381 inhabitants evaluated questionnaire-based exposure to tobacco, alcohol, tooth loss, pesticide exposure, preferred food temperature, and water source as potential risk factors in 228 cases (97.5% with dysplasia, 2.5% with ESCC) compared to 6932 control subjects without ESCC or dysplasia (58). Among these six potential risk factors, only water source showed a significant association with dysplasia/ESCC. Subjects with deep wells had lower risk of dysplasia/ESCC than persons with shallow wells (OR=0.72, 95% CI=0.54–0.96).

A summary comparison of risk factors evaluated for both ESCC and dysplasia is shown in Table 2. With the exceptions of smoking (a risk for ESCC but not dysplasia) and serum pepsinogens (a risk for dysplasia but not ESCC), the other risk factors studied were concordant for both dysplasia and ESCC.

4. Clinical Perspective and Natural History

Survival

The survival of ESCC is very poor, largely due to late development of symptoms and consequent late diagnosis. The most recent 5-year relative survival rate for esophageal cancer in the SEER registries (2001–2007) was 19% (72). In developing countries, however, where most of the ESCC cases occur, survival rates are much lower. A recent study from northeastern Iran reported a 5-year survival rate of 3.4% (73), which is probably a more typical figure in high-risk, low-resource populations.

Survival is dramatically dependent on the stage of disease at diagnosis: in SEER (2001–2007), the 5-year survival rates were 37%, 18%, and 3% for localized, regional, and distant disease, and in China, 5-year survival of patients with stage T1 ESCC has been reported to be 86% (74).

The large difference in survival by stage suggests that early detection of precursor lesions and early-stage cancers might offer a chance to significantly reduce mortality. The problem, of course, is how to identify individuals with these early treatable lesions, since virtually all of these people are asymptomatic. Thus the challenge is to risk-stratify asymptomatic people and then develop an accurate, patient-acceptable, and cost-effective way to screen high-risk groups and find the few individuals who need treatment.

Endoscopic Visualization of Dysplasia

One way to identify ESD and early ESCC is by endoscopy with Lugol's iodine staining. Iodine reversibly binds with glycogen, which is abundant in the superficial cells of normal esophageal squamous mucosa but is scant or absent in the rapidly dividing cells of significant esophagitis or dysplasia. Thus spraying Lugol's iodine solution on the

esophageal mucosa turns normal areas brown but leaves areas of severe esophagitis or dysplasia unstained. These negative image “unstained lesions” (USLs) can be endoscopically targeted for biopsy and, if appropriate, focal endoscopic therapy (Fig 4). The sensitivity of these USLs for the presence of high-grade (moderate or severe) ESD or early invasive ESCC is very high, around 95% in studies from China (75, 76), and the specificity (around 65%) is greatly improved after the biopsies are read, distinguishing between esophagitis and dysplasia.

Natural History of Dysplasia

The natural history of ESD has not been extensively studied, but some observations bearing on the progression of these lesions have been reported. As noted above, follow-up of untreated patients in a high-risk Chinese population with biopsy-proven mild, moderate and severe squamous dysplasia showed development of clinically diagnosed ESCC in 5%, 27%, and 65% after 3.5 years (4) and 24%, 50%, and 74% after 13.5 years (5). Another report of patients with moderate or severe dysplasia who were followed endoscopically for 16 months found that 22% with moderate dysplasia and 60% with severe dysplasia showed endoscopic (size) or histologic progression during this period (77). No similar follow-up studies of untreated patients with ESD have been reported from western populations. Thus, at least in China, ESD appears to progress over months to many years, depending on the grade. But based on the high cumulative incidence figures reported above, it is probable that severe dysplasia needs prompt treatment, moderate dysplasia needs treatment or periodic endoscopic follow-up, and mild dysplasia can be followed at longer intervals. There is a need for more studies evaluating the natural history of ESD, and a need for consensus clinical guidelines for treatment and patient follow-up and treating these lesions.

Treatment of Dysplasia

Several endoscopic methods are used to treat ESD. Excisional methods, in which the lesion is excised endoscopically, include endoscopic mucosal resection (EMR) using the “cap method” (78), EMR using the “banding method” (also called multiband mucosectomy, or MBM) (79), and endoscopic submucosal dissection (78, 80). Ablative methods, which burn the lesions in-situ, include multipolar electocoagulation (MPEC), argon plasma coagulation (APC), and radiofrequency ablation (RFA) (76). An advantage of the excisional methods is the preservation of the lesion in a surgical specimen, which can be reviewed pathologically to document the true extent of disease and evaluate the need for additional therapy, but a disadvantage is that they require greater endoscopic expertise to perform. All of these treatment methods are relatively new in high-risk areas, so the optimal clinical follow-up protocols are still being defined and the procedural costs and cost-benefit comparisons are still being evaluated.

5. Prospects and Implications for Prevention

Target and Strategy

Dysplasia, the ESCC precursor lesion, is a target for prevention strategies, including both chemoprevention and screening, even though there is not yet a strategy in place.

Chemoprevention

Chemoprevention emerged as a cancer prevention strategy in the 1980s, and ESCC was a target for prevention in two early nutrition intervention trials conducted in China. Results from those trials showed that supplementation with the combination of selenium/vitamin E/ beta-carotene reduced total mortality, total cancer mortality, and gastric cancer mortality and incidence in the Linxian General Population NIT, but no benefit was seen for esophageal cancer (48). No effect was seen on esophageal cancer incidence or mortality from

multivitamin supplementation in the Linxian Dysplasia NIT (81). The beneficial effects of selenium/vitamin E/beta-carotene on mortality were still evident up to 10 years after the cessation of supplementation in the Linxian General Population NIT, and reduced esophageal cancer mortality was also seen among younger participants (82).

There have been many more trials evaluating precursor and precursor-related lesions of the squamous esophagus than there have been trials with actual cancer endpoints. As with the cancer-endpoint-based prevention trials, these precursor trials have all been conducted in northern China. A total of 13 analyses (summarized in Table 3) have been published from 10 different interventions (83–94). All but two of the trials evaluated a nutritional intervention, including a variety of micronutrients (e.g., retinol, riboflavin, zinc, calcium, selenium, multivitamins), decaffeinated green tea, and freeze-dried strawberries, while a single trial evaluated antitumor B (a mixture of six Chinese herbs) (95) and a retinoid, and another tested celecoxib. Trial endpoints were typically histologic or cytologic regression or progression, or prevalence of dysplasia, with a few reports of other intermediate endpoint markers (e.g., prevalence of micronuclei or proliferation markers). Evidence for a beneficial effect on premalignancy was observed in four of these studies: the combination of retinol +riboflavin+zinc reduced micronuclei (84); multivitamins improved cytology (90); selenomethionine improved histology (92); and strawberries improved histology and reduced proliferation and expression of several cancer-related proteins (94). A benefit for cancer was observed for antitumor B (85) and riboflavin (85), and was suggested among persons whose communities received riboflavin-fortified salt (93).

Utility of Screening

The determination that ESD is the preneoplastic lesion for ESCC provides the possibility of screening not just for early stage ESCC, but also to screen for and treat the preneoplastic lesion itself in a manner analogous to screening and treating cervical dysplasia to prevent cervical cancer. A comprehensive system that uses chromoendoscopy and grade-specific therapy for ESD has the potential to reduce disease incidence and disease-specific mortality. In areas with very high rates of the disease it could even reduce total mortality. A community assignment trial in a high-incidence region of China has demonstrated that endoscopic screening and treatment reduced esophageal cancer incidence and mortality (unpublished data), but like all screening methodologies, the utility of this regimen remains speculative without confirmatory randomized trial data that prove that this method is beneficial, because there is clear evidence that early detection of cancer is not always beneficial because not all preneoplastic lesions progress and treatments may cause serious complications and side effects (96).

Furthermore, populations with high incidence rates of esophageal cancer tend to be poor and medically underserved. Endoscopic screening and treatment of an entire population would be expensive and would require many highly trained physicians and expensive equipment. Risk stratification to reduce the number of people needing screening would be useful, but this remains impractical based on demographic and easily collected exposure variables (59, 60). Alternatively, a simpler primary screening test that identifies subjects most likely to be positive for ESD could reduce the number of individuals needing endoscopic screening. Previous attempts to use balloon cytology (analogous to a Pap smear) to find subjects with ESD showed that this method was likely too insensitive and non-specific to be useful for full scale screening (55, 57). But improved molecular testing of retrieved esophageal cells has shown promise for the esophageal adenocarcinoma precursor, Barrett's esophagus (97), and may facilitate ESD screening as well.

6. Summary

ESCC is the predominant form of EC worldwide, particularly in developing countries, and has among the poorest survival of all cancers. ESD is the precursor lesion for ESCC and the prevalence of ESD is 25% or more among adults in areas of north central China where ESCC rates are highest. Risk factors for ESD appear largely to parallel those of invasive ESCC. The high prevalence of ESD in high-risk areas, coupled with simple but sensitive endoscopic-based methods to detect dysplasia, suggest that early detection of persons with precursor lesions for subsequent prevention strategies such as chemoprevention or endoscopic therapy offer substantial promise for the reduction of ESCC mortality. Future research on ESD and ESCC should focus on finding additional modifiable risk factors and on identifying biomarkers to incorporate into patient-acceptable early detection strategies.

ABBREVIATIONS USED

ESCC	esophageal squamous cell carcinoma
ESD	endoscopic submucosal dissection
EC	esophageal cancer
EAC	esophageal adenocarcinoma
GWAS	genome-wide association study
NIT	Nutrition Intervention Trials
NOS	not otherwise specified
ESD	esophageal squamous dysplasia
IHC	immunohistochemistry
LOH	loss of heterozygosity
OR	odds ratio
PG	pepsinogen
USL	unstained lesions
EMR	endoscopic mucosal resection
MBM	multiband mucosectomy
MPEC	multipolar electrocoagulation
APC	argon plasma coagulation
RFA	radiofrequency ablation
EGD	esophagogastroduodenoscopy
NA	information not available
RCT	randomized controlled trials

Reference List

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.* 2011; 61:69–90. [PubMed: 21296855]
2. Munoz N, Crespi M, Grassi A, Qing WG, Qiong S, Cai LZ. Precursor lesions of oesophageal cancer in high-risk populations in Iran and China. *Lancet.* 1982; 1:876–879. [PubMed: 6122101]

3. Qiu SL, Yang GR. Precursor lesions of esophageal cancer in high-risk populations in Henan Province, China. *Cancer*. 1988; 62:551–557. [PubMed: 3390795]
4. Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, et al. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. *Cancer*. 1994; 74:1686–1692. [PubMed: 8082069]
5. Wang GQ, Abnet CC, Shen Q, Lewin KJ, Sun XD, Roth MJ, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. *Gut*. 2005; 54:187–192. [PubMed: 15647178]
6. Ismail-Beigi F, Horton PF, Pope CE. Histological consequences of gastroesophageal reflux in man. *Gastroenterol*. 1970; 58:163–174.
7. Weinstein WM, Bogoch ER, Bowes KL. The normal human esophageal mucosa: a histological reappraisal. *Gastroenterol*. 1975; 68:40–44.
8. Tumor Prevention TaRGCH, Esophageal Cancer Research Group CAoMSP, Linhsien County People's Hospital H. Pathology of early esophageal squamous carcinoma. *Chin Med J*. 1977; 3:180–192. [PubMed: 410603]
9. Mitros, FA. Inflammatory and neoplastic diseases of the esophagus. In: Appleman, HD., editor. *Pathology of the esophagus, stomach and duodenum*. New York: Churchill Livingstone; 1984. p. 1-35.
10. Dawsey SM, Lewin KJ, Liu FS, Wang GQ, Shen Q. Esophageal morphology from Linxian, China. Squamous histologic findings in 754 patients. *Cancer*. 1994; 73:2027–2037. [PubMed: 8156507]
11. Hu N, Huang J, Emmert-Buck MR, Tang ZZ, Roth MJ, Wang C, et al. Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China. *Clin Cancer Res*. 2001; 7:883–891. [PubMed: 11309337]
12. Abedi-Ardekani B, Kamangar F, Sotoudeh M, Villar S, Islami F, Aghcheli K, et al. Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran. *PLoS One*. 2011; 6:e29488. [PubMed: 22216294]
13. Xing EP, Nie Y, Wang LD, Yang GY, Yang CS. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. *Carcinogenesis*. 1999; 20:77–84. [PubMed: 9934853]
14. Su H, Hu N, Yang HH, Wang C, Takikita M, Wang QH, et al. Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes. *Clin Cancer Res*. 2011; 17:2955–2966. [PubMed: 21385931]
15. Agrawal N, Jiao Y, Bettegowda C, Hutfless SM, Wang Y, David S, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. *Cancer Discov*. 2012; 2:899–905. [PubMed: 22877736]
16. Wang LD, Hong JY, Qiu SL, Gao H, Yang CS. Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. *Cancer Res*. 1993; 53:1783–1787. [PubMed: 8467496]
17. Roye GD, Myers RB, Brown D, Poczatek R, Beenken SW, Grizzle WE. CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus. *Int J Cancer*. 1996; 69:254–258. [PubMed: 8797863]
18. Zhou Q, Dong WL, Du F, Zhou Y, Rui ZY, Liu B, et al. Changes of TGFbeta1 and TGFbetaRII expression in esophageal precancerous and cancerous lesions: a study of a high-risk population in Henan, northern China. *Dis Esophagus*. 2002; 15:74–79. [PubMed: 12060047]
19. Chen H, Wang LD, Guo M, Gao SG, Guo HQ, Fan ZM, et al. Alterations of p53 and PCNA in cancer and adjacent tissues from concurrent carcinomas of the esophagus and gastric cardia in the same patient in Linzhou, a high incidence area for esophageal cancer in northern China. *World J Gastroenterol*. 2003; 9:16–21. [PubMed: 12508343]
20. Kimos MC, Wang S, Borkowski A, Yang GY, Yang CS, Perry K, et al. Esophagin and proliferating cell nuclear antigen (PCNA) are biomarkers of human esophageal neoplastic progression. *Int J Cancer*. 2004; 111:415–417. [PubMed: 15221970]
21. Xue LY, Hu N, Song YM, Zou SM, Shou JZ, Qian LX, et al. Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma. *BMC Cancer*. 2006; 6:296. [PubMed: 17187659]

22. Bai P, Xiao X, Zou J, Cui L, Bui Nguyen TM, Liu J, et al. Expression of p14(ARF), p15(INK4b), p16(INK4a) and skp2 increases during esophageal squamous cell cancer progression. *Exp Ther Med.* 2012; 3:1026–1032. [PubMed: 22970012]
23. Yang L, Wang LS, Chen XL, Gatalica Z, Qiu S, Liu Z, et al. Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. *Int J Biochem Mol Biol.* 2012; 3:46–57. [PubMed: 22509480]
24. Shimada M, Yanagisawa A, Kato Y, Inoue M, Shiozaki H, Monden M, et al. Genetic mechanisms in esophageal carcinogenesis: frequent deletion of 3p and 17p in premalignant lesions. *Genes Chromosomes Cancer.* 1996; 15:165–169. [PubMed: 8721680]
25. Roth MJ, Hu N, Emmert-Buck MR, Wang QH, Dawsey SM, Li G, et al. Genetic progression and heterogeneity associated with the development of esophageal squamous cell carcinoma. *Cancer Res.* 2001; 61:4098–4104. [PubMed: 11358832]
26. Shima H, Hiyama T, Tanaka S, Ito M, Kitadai Y, Yoshihara M, et al. Frequent loss of heterozygosity on chromosome 10p14-p15 in esophageal dysplasia and squamous cell carcinoma. *Oncol Rep.* 2004; 12:333–337. [PubMed: 15254698]
27. Liu M, Zhang F, Liu S, Zhao W, Zhu J, Zhang X. Loss of heterozygosity analysis of microsatellites on multiple chromosome regions in dysplasia and squamous cell carcinoma of the esophagus. *Exp Ther Med.* 2011; 2:997–1001. [PubMed: 22977611]
28. Gao H, Wang LD, Zhou Q, Hong JY, Huang TY, Yang CS. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. *Cancer Res.* 1994; 54:4342–4346. [PubMed: 8044781]
29. Nie Y, Liao J, Zhao X, Song Y, Yang GY, Wang LD, et al. Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. *Carcinogenesis.* 2002; 23:1713–1720. [PubMed: 12376481]
30. Roth MJ, Abnet CC, Hu N, Wang QH, Wei WQ, Green L, et al. p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. *Oncol Rep.* 2006; 15:1591–1597. [PubMed: 16685400]
31. Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, Kambara T, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. *Gut.* 2007; 56:13–19. [PubMed: 16785283]
32. Adams L, Roth MJ, Abnet CC, Dawsey SP, Qiao YL, Wang GQ, et al. Promoter methylation in cytology specimens as an early detection marker for esophageal squamous dysplasia and early esophageal squamous cell carcinoma. *Cancer Prev Res (Phila).* 2008; 1:357–361. [PubMed: 19137073]
33. Lu J, Liu Z, Xiong M, Wang Q, Wang X, Yang G, et al. Gene expression profile changes in initiation and progression of squamous cell carcinoma of esophagus. *Int J Cancer.* 2001; 91:288–294. [PubMed: 11169949]
34. Zhou J, Zhao LQ, Xiong MM, Wang XQ, Yang GR, Qiu ZL, et al. Gene expression profiles at different stages of human esophageal squamous cell carcinoma. *World J Gastroenterol.* 2003; 9:9–15. [PubMed: 12508342]
35. Kumar A, Chatopadhyay T, Raziuddin M, Ralhan R. Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma using cDNA microarray. *Int J Cancer.* 2007; 120:230–242. [PubMed: 17068819]
36. Killian J, Roth M, Singh P, Walker R, Chen Y, Wang GQ, et al. Large scale DNA methylation profiling and high-resolution comparative genomic hybridization of preneoplastic and invasive esophageal squamous cell carcinoma: Discovery of early detection markers. *Cancer Prev Res (Phila).* 2008; 1:B50.
37. Robertson EV, Jankowski JA. Genetics of gastroesophageal cancer: paradigms, paradoxes, and prognostic utility. *Am J Gastroenterol.* 2008; 103:443–449. [PubMed: 17925001]
38. Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, et al. A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. *Nat Genet.* 2010; 42:764–767. [PubMed: 20729852]

39. Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, et al. Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. *Nat Genet.* 2010; 42:759–763. [PubMed: 20729853]
40. Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. *Nat Genet.* 2011; 43:679–684. [PubMed: 21642993]
41. Wu C, Kraft P, Zhai K, Chang J, Wang Z, Li Y, et al. Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. *Nat Genet.* 2012; 44:1090–1097. [PubMed: 22960999]
42. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, et al. Performance of common genetic variants in breast-cancer risk models. *N Engl J Med.* 2010; 362:986–993. [PubMed: 20237344]
43. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. *J Natl Cancer Inst.* 2003; 95:1404–1413. [PubMed: 13130116]
44. Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. *Int J Cancer.* 2005; 113:456–463. [PubMed: 15455378]
45. Gao Y, Hu N, Han XY, Ding T, Giffen C, Goldstein AM, et al. Risk factors for esophagus and gastric cancers in Shanxi Province, China: A case-control study. *Cancer Epidemiol.* 2011; 35:e91–e99. [PubMed: 21846596]
46. Nasrollahzadeh D, Kamangar F, Aghcheli K, Sotoudeh M, Islami F, Abnet CC, et al. Opium, tobacco, and alcohol use in relation to esophageal squamous cell carcinoma in a high-risk area of Iran. *Br J Cancer.* 2008; 98:1857–1863. [PubMed: 18475303]
47. Abedi-Ardekani B, Kamangar F, Hewitt SM, Hainaut P, Sotoudeh M, Abnet CC, et al. Polycyclic aromatic hydrocarbon exposure in esophageal tissue and risk of esophageal squamous cell carcinoma in north-eastern Iran. *Gut.* 2010; 59:1178–1183. [PubMed: 20584779]
48. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. *J Natl Cancer Inst.* 1993; 85:1483–1492. [PubMed: 8360931]
49. Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. *J Natl Cancer Inst.* 2000; 92:1753–1763. [PubMed: 11058618]
50. Abnet CC, Qiao YL, Dawsey SM, Buckman DW, Yang CS, Blot WJ, et al. Prospective study of serum retinol, beta-carotene, beta-cryptoxanthin, and lutein/zeaxanthin and esophageal and gastric cancers in China. *Cancer Causes Control.* 2003; 14:645–655. [PubMed: 14575362]
51. Taylor PR, Qiao YL, Abnet CC, Dawsey SM, Yang CS, Gunter EW, et al. Prospective study of serum vitamin E levels and esophageal and gastric cancers. *J Natl Cancer Inst.* 2003; 95:1414–1416. [PubMed: 13130117]
52. Murphy G, Fan JH, Mark SD, Dawsey SM, Selhub J, Wang J, et al. Prospective study of serum cysteine levels and esophageal and gastric cancers in China. *Gut.* 2011; 60:618–623. [PubMed: 21242262]
53. Islami F, Pourshams A, Nasrollahzadeh D, Kamangar F, Fahimi S, Shakeri R, et al. Tea drinking habits and esophageal cancer in a high risk area in northern Iran: population based case-control study. *BMJ.* 2009; 338:b929. [PubMed: 19325180]
54. Crespi M, Munoz N, Grassi A, Aramesh B, Amiri G, Mojtabai A, et al. Esophageal lesions in northern Iran: a premalignant condition? *Lancet.* 1979; 2:217–221. [PubMed: 89331]
55. Roth MJ, Liu SF, Dawsey SM, Zhou B, Copeland C, Wang GQ, et al. Cytologic detection of esophageal squamous cell carcinoma and precursor lesions using balloon and sponge samplers in asymptomatic adults in Linxian, China. *Cancer.* 1997; 80:2047–2059. [PubMed: 9392326]
56. Lu XJ, Chen ZF, Guo CL, Li SS, Bai WL, Jin GL, et al. Endoscopic survey of esophageal cancer in a high-risk area of China. *World J Gastroenterol.* 2004; 10:2931–2935. [PubMed: 15378767]

57. Pan QJ, Roth MJ, Guo HQ, Kochman ML, Wang GQ, Henry M, et al. Cytologic detection of esophageal squamous cell carcinoma and its precursor lesions using balloon samplers and liquid-based cytology in asymptomatic adults in Linxian, China. *Acta Cytol.* 2008; 52:14–23. [PubMed: 18323271]
58. He Z, Zhao Y, Guo C, Liu Y, Sun M, Liu F, et al. Prevalence and risk factors for esophageal squamous cell cancer and precursor lesions in Anyang, China: a population-based endoscopic survey. *Br J Cancer.* 2010; 103:1085–1088. [PubMed: 20700119]
59. Etemadi A, Abnet CC, Golozar A, Malekzadeh R, Dawsey SM. Modeling the risk of esophageal squamous cell carcinoma and squamous dysplasia in a high risk area in Iran. *Arch Iran Med.* 2012; 15:18–21. [PubMed: 22208438]
60. Wei WQ, Abnet CC, Lu N, Roth MJ, Wang GQ, Dye BA, et al. Risk factors for oesophageal squamous dysplasia in adult inhabitants of a high risk region of China. *Gut.* 2005; 54:759–763. [PubMed: 15888779]
61. Abnet CC, Chen W, Dawsey SM, Wei WQ, Roth MJ, Liu B, et al. Serum 25(OH)-vitamin D concentration and risk of esophageal squamous dysplasia. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:1889–1893. [PubMed: 17855710]
62. Kamangar F, Diaw L, Wei WQ, Abnet CC, Wang GQ, Roth MJ, et al. Serum pepsinogens and risk of esophageal squamous dysplasia. *Int J Cancer.* 2009; 124:456–460. [PubMed: 18844222]
63. Li T, Lu ZM, Chen KN, Guo M, Xing HP, Mei Q, et al. Human papillomavirus type 16 is an important infectious factor in the high incidence of esophageal cancer in Anyang area of China. *Carcinogenesis.* 2001; 22:929–934. [PubMed: 11375901]
64. Zhou XB, Guo M, Quan LP, Zhang W, Lu ZM, Wang QH, et al. Detection of human papillomavirus in Chinese esophageal squamous cell carcinoma and its adjacent normal epithelium. *World J Gastroenterol.* 2003; 9:1170–1173. [PubMed: 12800217]
65. Kamangar F, Qiao YL, Schiller JT, Dawsey SM, Fears T, Sun XD, et al. Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China. *Int J Cancer.* 2006; 119:579–584. [PubMed: 16496409]
66. Koshiol J, Wei WQ, Kreimer AR, Chen W, Gravitt P, Ren JS, et al. No role for human papillomavirus in esophageal squamous cell carcinoma in China. *Int J Cancer.* 2010; 127:93–100. [PubMed: 19918949]
67. Sitas F, Egger S, Urban MI, Taylor PR, Abnet CC, Boffetta P, et al. InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. *J Natl Cancer Inst.* 2012; 104:147–158. [PubMed: 22228147]
68. Guo F, Liu Y, Wang X, He Z, Weiss NS, Madeleine MM, et al. Human papillomavirus infection and esophageal squamous cell carcinoma: a case-control study. *Cancer Epidemiol Biomarkers Prev.* 2012; 21:780–785. [PubMed: 22337534]
69. Gao GF, Roth MJ, Wei WQ, Abnet CC, Chen F, Lu N, et al. No association between HPV infection and the neoplastic progression of esophageal squamous cell carcinoma: result from a cross-sectional study in a high-risk region of China. *Int J Cancer.* 2006; 119:1354–1359. [PubMed: 16615110]
70. Chang F, Shen Q, Zhou J, Wang C, Wang D, Syrjanen S, et al. Detection of human papillomavirus DNA in cytologic specimens derived from esophageal precancer lesions and cancer. *Scand J Gastroenterol.* 1990; 25:383–388. [PubMed: 2159655]
71. Chang F, Syrjanen S, Shen Q, Ji HX, Syrjanen K. Human papillomavirus (HPV) DNA in esophageal precancer lesions and squamous cell carcinomas from China. *Int J Cancer.* 1990; 45:21–25. [PubMed: 2153638]
72. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin.* 2012; 62:10–29. [PubMed: 22237781]
73. Aghcheli K, Marjani HA, Nasrollahzadeh D, Islami F, Shakeri R, Sotoudeh M, et al. Prognostic factors for esophageal squamous cell carcinoma--a population-based study in Golestan Province, Iran, a high incidence area. *PLoS One.* 2011; 6:e22152. [PubMed: 21811567]
74. Wang GQ, Jiao GG, Chang FB, Fang WH, Song JX, Lu N, et al. Long-term results of operation for 420 patients with early squamous cell esophageal carcinoma discovered by screening. *Ann Thorac Surg.* 2004; 77:1740–1744. [PubMed: 15111177]

75. Dawsey SM, Fleischer DE, Wang GQ, Zhou B, Kidwell JA, Lu N, et al. Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. *Cancer*. 1998; 83:220–231. [PubMed: 9669803]
76. Bergman JJ, Zhang YM, He S, Weusten B, Xue L, Fleischer DE, et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. *Gastrointest Endosc*. 2011; 74:1181–1190. [PubMed: 21839994]
77. Dawsey SM, Fleischer DE, Wang GQ, Kidwell JA, Zhou B, Tio TL, et al. Endoscopic and histologi progression of untreated squamous esophageal neoplasia in asymptomatic patients from Linxian, China: implications for screening. *Gastroenterol*. 1997; 112:A553.
78. Inoue H, Minami H, Kaga M, Sato Y, Kudo SE. Endoscopic mucosal resection and endoscopic submucosal dissection for esophageal dysplasia and carcinoma. *Gastrointest Endosc Clin N Am*. 2010; 20:25–vi. [PubMed: 19951792]
79. Zhang Y, Boerwinkel DF, He S, Weusten BLAM, Xue L, Fleischer DE, et al. Endoscopic mucosal resection and endoscopic submucosal dissection for esophageal dysplasia and carcinoma. *Endoscopy*. 2012 In press.
80. Oyama T, Tomori A, Hotta K, Morita S, Kominato K, Tanaka M, et al. Endoscopic submucosal dissection of early esophageal cancer. *Clin Gastroenterol Hepatol*. 2005; 3:S67–S70. [PubMed: 16013002]
81. Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. *J Natl Cancer Inst*. 1993; 85:1492–1498. [PubMed: 8360932]
82. Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, et al. Total and cancer mortality following supplementation with vitamins and minerals: Follow-up of the Linxian General Population Nutrition Intervention Trial. *J Natl Cancer Inst*. 2009; 101:507–518. [PubMed: 19318634]
83. Munoz N, Wahrendorf J, Bang LJ, Crespi M, Thurnham DI, Day NE, et al. No effect of riboflavine, retinol, and zinc on prevalence of precancerous lesions of oesophagus. Randomised double-blind intervention study in high-risk population of China. *Lancet*. 1985; 2:111–114. [PubMed: 2862315]
84. Munoz N, Hayashi M, Bang LJ, Wahrendorf J, Crespi M, Bosch FX. Effect of riboflavin, retinol, and zinc on micronuclei of buccal mucosa and of esophagus: a randomized double-blind intervention study in China. *J Natl Cancer Inst*. 1987; 79:687–691. [PubMed: 3477659]
85. Lin PZ, Zhang JS, Cao SG, Han R, Xu SP, Xu ZP, et al. Second line prevention from esophageal cancer inhibitory therapy to block precancerous lesions. *Chin J Cancer Res*. 1988; 1:37–46.
86. Wang LD, Qiu SL, Yang GR, Lipkin M, Newmark HL, Yang CS. A randomized double-blind intervention study on the effect of calcium supplementation on esophageal precancerous lesions in a high-risk population in China. *Cancer Epidemiol Biomarkers Prev*. 1993; 2:71–78. [PubMed: 8420615]
87. Wang GQ, Dawsey SM, Li JY, Taylor PR, Li B, Blot WJ, et al. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. *Cancer Epidemiol Biomarkers Prev*. 1994; 3:161–166. [PubMed: 8049638]
88. Dawsey SM, Wang GQ, Taylor PR, Li JY, Blot WJ, Li B, et al. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the Dysplasia Trial in Linxian, China. *Cancer Epidemiol Biomarkers Prev*. 1994; 3:167–172. [PubMed: 8049639]
89. Rao M, Liu FS, Dawsey SM, Yang K, Lipkin M, Li JY, et al. Effects of vitamin/mineral supplementation on the proliferation of esophageal squamous epithelium in Linxian, China. *Cancer Epidemiol Biomarkers Prev*. 1994; 3:277–279. [PubMed: 8019379]
90. Mark SD, Liu SF, Li JY, Gail MH, Shen Q, Dawsey SM, et al. The effect of vitamin and mineral supplementation on esophageal cytology: results from the Linxian Dysplasia Trial. *Int J Cancer*. 1994; 57:162–166. [PubMed: 8157352]

91. Wang LD, Zhou Q, Feng CW, Liu B, Qi YJ, Zhang YR, et al. Intervention and follow-up on human esophageal precancerous lesions in Henan, northern China, a high-incidence area for esophageal cancer. *Gan To Kagaku Ryoho*. 2002; 29(Suppl 1):159–172. [PubMed: 11890101]
92. Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. *Gastroenterol*. 2005; 129:863–873.
93. He Y, Ye L, Shan B, Song G, Meng F, Wang S. Effect of riboflavin-fortified salt nutrition intervention on esophageal squamous cell carcinoma in a high incidence area, China. *Asian Pac J Cancer Prev*. 2009; 10:619–622. [PubMed: 19827881]
94. Chen T, Yan F, Qian J, Guo M, Zhang H, Tang X, et al. Randomized phase II trial of lyophilized strawberries in patients with dysplastic precancerous lesions of the esophagus. *Cancer Prev Res (Phila)*. 2012; 5:41–50. [PubMed: 22135048]
95. Lin P, Zhang J, Rong Z, Han R, Xu S, Gao R, et al. Studies on medicamentous inhibitory therapy for esophageal precancerous lesions-3-and 5-year inhibitory effects of antitumor-B, retinamide and riboflavin. *Proc Chin Acad Med Sci Peking Union Med Coll*. 1990; 5:121–129. [PubMed: 2098764]
96. Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. *J Natl Cancer Inst*. 2006; 98:748–756. [PubMed: 16757699]
97. Kadri SR, Lao-Sirieix P, O'Donovan M, Debiram I, Das M, Blazeby JM, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. *BMJ*. 2010; 341:c4372. [PubMed: 20833740]

Figure 1.
Esophageal cancer incidence worldwide in 2008 (men)

Figure 2.
 ESCC precursor lesions: Cumulative incidences and relative risks for the development of
 ESCC over 13.5-years of follow-up by initial histology (N=670)

Normal

Mild dysplasia

Moderate dysplasia

Severe dysplasia

Figure 3.
Histologic appearance of normal squamous epithelial and mild, moderate, and severe esophageal squamous dysplasia

Without Lugol's

With Lugol's

Figure 4.

Esophageal squamous dysplasia without and with Lugol's iodine staining. An unstained lesion becomes readily apparent after topical application of Lugol's iodine solution which can then be targeted for biopsy.

Table 1

Prevalence of esophageal squamous cell carcinoma precursor lesions

Year reported	1st author (ref no.)	Location	Population			EGD/ ¹ Mucosal iodine	Dysplasia			All dysplasia	Invasive ESCC	All dysplasia by gender
			Number	Age (yrs)	Gender		Prior dysplasia	Mild	Moderate	Severe		
1979	Crespi (54)	Gonbad, Iran	430	15 – 70	M+F	None	None	NA ²	NA	NA	NA	5% M, 3% F
1982	Munoz (2)	Linxian, PRC	527	25 – 55+	M+F	One-third	One-third	NA	NA	NA	0.9%	8% M, 8% F
1988	Qiu (3)	Linxian & Boaixian, PRC	1043	NA	M+F	Most	Most	NA	NA	NA	1.8%	17% M, 18% F
1988	Qiu (3)	Huixian, PRC	300	35 – 65	M+F	NA	NA	NA	NA	NA	2.7%	37% M, 41% F
		Fanxian, PRC	300	35 – 65	M+F	NA	NA	NA	NA	NA	1.0%	6% M, 4% F
1994	Dawsey (10)	Linxian, PRC	754	40 – 69	M+F	All	All	10.6%	4.6%	5.8%	4.6%	
1997	Roth (55)	Linxian, PRC	439	50 – 69	M+F	None	None	12.0%	10.0%	6.0%	4.0%	
2004	Lu (56)	Cixian, PRC	2013	40 – 69	M+F	NA	NA	8.6%	7.8%	2.6%	0.7%	26% M, 18% F
2008	Pan (57)	Linxian, PRC	725	50 – 64	M+F	NA	NA	14.0%	12.0%	5.0%	0.6%	
2010	He (58)	Anyang, PRC	7381	25 – 65	M+F	NA	NA	2.6%	0.2%	0.2%	0.1%	
2012	Etemadi (59)	Gonbad, Iran	724	NA	M+F	None	None	NA	NA	NA	NA	

¹EGD = esophagogastroduodenoscopy

²NA = information not available

Table 2

Comparison of risk factors evaluated for both ESCC and esophageal squamous dysplasia in China

Risk factor	ESCC (ref no.)	Dysplasia (Linxian) (ref no.)	Dysplasia (Anyang) (ref no.)
Gender	No (44)	No (60)	No (58)
Tobacco smoking	Yes (44–45)	No (60)	No (58)
Alcohol drinking	No (44–45)	No (60)	No (58)
Family history of cancer	Yes (44)	Yes (60)	NA ¹
Tooth loss	Yes ²	Yes (60)	No (58)
Serum vitamin D	Yes ³	Yes (61)	NA
Water source	Yes (44)	NA	Yes (58)
Serum pepsinogens	No ⁴	Yes (62)	NA
Hot liquids/food	No & Yes (44 & 45)	NA	No (58)
HPV	No & Yes (65–67 & 63–64,68,70–71)	No & Yes (69 & 70–71)	Yes (63)

¹ NA = information not available² Abnet CC et al, Cancer Causes Control 2001;12:847-54.³ Chen W et al, Br J Cancer 2007;97:123-8.⁴ Ren JS et al, Gut 2009;58:636-42

Table 3
Chemoprevention trials evaluating precursor and precursor-related lesions of the squamous esophagus in north China

Year reported	1st author (ref no.)	Location	Population	Design	Intervention	Duration	Endpoint(s)	Result
1985	Munoz (83)	Huixian	N=610 35–64yr	2-arm RCT ¹	Retinol+riboflavin+zinc (vs placebo)	13.5mo	Esophagitis (histo)	No effect
1987	Munoz (84)	Huixian	N=200 35–64yr	2-arm RCT	Retinol+riboflavin+zinc (vs placebo)	13.5mo	Micronuclei in esophageal cells (histo)	Benefit [Intervention 0.19% vs placebo 0.31%]
1988	Lin (85)	Heshun, Linxian	N=1728 severe dysplasia	3-arm RCT	Antitumor B, Retinamide (vs placebo)	3yr	Cytology regress/progress	No effect for antitumor B ² No effect for retinamide ²
1988	Lin (85)	Heshun, Linxian	N=2412 mild dysplasia	2-arm RCT	Riboflavin (vs placebo)	3yr	Cytology regress/progress	No effect ³
1993	Wang (86)	Huixian	N=200 non-normal 30–60+yr	2-arm RCT	Calcium (vs placebo)	11mo	Histology regress/progress Proliferation	No effect on histology No effect on proliferation
1994	Wang (87)	Linxian	N=391 40–69yr	2×4 fractional factorial RCT	4 micronutrient groups/factors	5.25yr	Dysplasia/cancer (histo)	No effect for any of 4 factors
1994	Dawsey (88)	Linxian	N=833 & 396 dysplasia 40–69yr	2-arm RCT	Multivitamins (vs placebo)	2.5 & 6yr	Dysplasia/cancer (histo)	No effect at either time point
1994	Rao (89)	Linxian	N=512 dysplasia 40–69yr	2-arm RCT	Multivitamins (vs placebo)	2.5yr	Proliferation (histo)	No effect overall
1994	Mark (90)	Linxian	N=3318 dysplasia	2-arm RCT	Multivitamins	2.5 & 6yr	Cytology regress/progress	Benefit

Year reported	1st author (ref no.)	Location	Population	Design	Intervention	Duration	Endpoint(s)	Result
			40–69yr		(vs placebo)			[Intervention OR for regression to nondysplasia = 1.23]
2002	Wang (91)	Huixian	N=200 non-normal 30–60+yr	2-arm RCT	Decaffeinated green tea (vs placebo)	12mo	Histology regress/progress	No effect
2005	Limburg (92)	Linxian	N=238 dysplasia 34–68yr	2×2 factorial RCT	Selenomethionine, Celecoxib	11mo	Histology regress/progress	Benefit in mild dysplasia [Selenomethionine increased regression & decreased progression ≈2-fold each]
2009	He (93)	Cixian	N=9 townships (11,392 persons) fortified vs 12 townships (10,711 persons) unfortified 40–69yr (randomly selected)	Endoscopy comparison of 950 fortified vs 1300 unfortified group persons	Riboflavin-fortified salt (vs unfortified salt)	6yr	Dysplasia (histo) Cancer (histo)	No effect on dysplasia Suggested benefit for cancer [Intervention 1.6% vs placebo 3.1%]
2011	Chen (94)	Henan, Shandong	N=75 dysplasia	37 low dose, 38 high dose (randomized to dose group)	Freeze-dried strawberries (low, high doses)	6mo	Histology regress/progress Proliferation	Benefit for high dose [reduced histology grade in 81%] Benefit for high dose [reduced Ki-67 labeling by 38%] Benefit for high dose [reduced iNOS 80%, COX-2 63%, NFKB-p65 63%, pS6 73%]

¹ RCT = randomized controlled trial

² Neither antitumor B nor retinamide improved cytology regression/progression overall, but antitumor B reduced the number of new cancers (3.9% for antitumor B group vs 8.3% for placebo group)

³ Riboflavin did not improve cytology regression/progression overall, but reduced the number of new cancers (1.7% for riboflavin group vs 2.1% for placebo group)